Carmen Scheibenbogen (born 16 March 1962) is a German immunologist who is the acting director of the Institute for Medical Immunology of the Charité university hospital in Berlin.[1][2] She specialises in hematology (blood and blood diseases), oncology and immunology.[2] She leads the Outpatient Clinic for Immunodeficiency and the Fatigue Centre at the Charité hospital.[3] She is one of the few doctors specialised in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in Germany,[4] and also researches long COVID.[1]
Career
editScheibenborgen started her study of medicine in Bonn in 1982 and finished it in Marburg. During her studies she spent half a year in Denver in the US, working in a hospital there, and developed a passion for the immune system. She continued as a research assistant at the University of Freiburg, and trained in rheumatology and hemo-oncology in Heidelberg.[5]
In 1998 she founded a group around tumor immunology at the Charité university hospital in Berlin, and became the director of the Institute of Immunology there in 2007. Her work moved towards care for myalgic encephalomyelitis/chronic fatigue syndrome a few years later, and after realising care options were limited, focussed on expanding these. In 2015 she founded the European Network on ME/CFS and three years later she opened the Charité Fatigue Centre. She received a €10 million grant build a study group to test treatments for people with ME/CFS from the German Federal Ministry of Education and Research.[5]
In 2022, she received the German Cross of Merit for her work around ME/CFS.[1] Patients and their family had put her name forward to be considered.[6]
Research
editScheibenborgen studies the role of autoimmunity in ME/CFS.[7] Her group found that in a subset of people with ME/CFS, there are autoantibodies to neurotransmitter and nuclear receptors.[8] She hypothesized in a series of papers with Klaus Wirth that autoimmunity may explain the diverse symptoms of ME/CFS in a subset of patients, including muscle weakness and the neurological symptoms.[9][10][11]
Since the start of the COVID-19 pandemic, she has researched therapeutic options for people with long COVID.[1]
Selected publications
edit- Leser HG, Gross V, Scheibenbogen C, et al. (September 1991). "Elevation of serum interleukin-6 concentration precedes acute-phase response and reflects severity in acute pancreatitis". Gastroenterology. 101 (3): 782–5. doi:10.1016/0016-5085(91)90539-w. PMID 1907253.
- Nagorsen D, Scheibenbogen C, Marincola FM, et al. (October 2003). "Natural T cell immunity against cancer". Clinical Cancer Research. 9 (12): 4296–303. PMID 14555498.
- Rasa S, Nora-Krukle Z, Henning N, Eliassen E, Shikova E, Harrer T, Scheibenbogen C, Murovska M, Prusty BK (October 2018). "Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)". Journal of Translational Medicine. 16 (1): 268. doi:10.1186/s12967-018-1644-y. PMC 6167797. PMID 30285773.
- Sotzny F, Blanco J, Capelli E, Castro-Marrero J, Steiner S, Murovska M, Scheibenbogen C (June 2018). "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome – Evidence for an autoimmune disease". Autoimmunity Reviews. 17 (6): 601–609. doi:10.1016/j.autrev.2018.01.009. PMID 29635081.
- Kedor C, Freitag H, Meyer-Arndt L, Wittke K, Hanitsch LG, Zoller T, Steinbeis F, Haffke M, Rudolf G, Heidecker B, Bobbert T, Spranger J, Volk HD, Skurk C, Konietschke F, Paul F, Behrends U, Bellmann-Strobl J, Scheibenbogen C (August 2022). "A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity". Nature Communications. 13 (1): 5104. Bibcode:2022NatCo..13.5104K. doi:10.1038/s41467-022-32507-6. PMC 9426365. PMID 36042189.
References
edit- ^ a b c d Richter-Kuhlmann, Eva (4 November 2022). "Carmen Scheibenbogen: Hoffnung für Long-COVID-Erkrankte". Deutsches Ärzteblatt (in German). Deutscher Ärzteverlag GmbH, Redaktion Deutsches. Retrieved 2 January 2024.
- ^ a b "Prof. Dr. med. Carmen Scheibenbogen". Charité. Retrieved 7 January 2024.
- ^ "Internationale Konferenz: ME/CFS – eine kaum erforschte Krankheit". tagesschau.de (in German). 15 May 2023. Retrieved 2 January 2024.
- ^ "Ordensverleihung zum Tag der Deutschen Einheit". Der Bundespräsident (in German). Retrieved 5 January 2024.
- ^ a b Dotti, Anna (2 January 2023). "Porträt von Carmen Scheibenbogen". Tagesspiegel (in German). Retrieved 5 January 2024.
- ^ Hildebrandt, Stefanie (4 October 2022). "Berliner Charité-Professorin ist die einzige Hoffnung für viele Long-Covid-Erkrankte". Berliner Kurier (in German). Retrieved 26 January 2024.
- ^ Tucker, Miriam (1 September 2021). "Emerging data point to underlying autoimmunity in ME/CFS". www.mdedge.com. Retrieved 7 January 2024.
- ^ Sotzny F, Blanco J, Capelli E, Castro-Marrero J, Steiner S, Murovska M, Scheibenbogen C, et al. (European Network on ME/CFS (EUROMENE)) (June 2018). "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome – Evidence for an autoimmune disease". Autoimmunity Reviews. 17 (6): 601–609. doi:10.1016/j.autrev.2018.01.009. PMID 29635081.
- ^ Wirth K, Scheibenbogen C (June 2020). "A Unifying Hypothesis of the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Recognitions from the finding of autoantibodies against ß2-adrenergic receptors". Autoimmunity Reviews. 19 (6): 102527. doi:10.1016/j.autrev.2020.102527. PMID 32247028.
- ^ Wirth, Klaus J.; Scheibenbogen, Carmen; Paul, Friedemann (11 January 2022). "An attempt to explain the neurological symptoms of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". Journal of Translational Medicine. 20 (1): 25. doi:10.1186/s12967-021-03216-3. ISSN 1479-5876. PMC 8751276. PMID 35016692.
- ^ Wirth, Klaus J.; Scheibenbogen, Carmen (21 April 2021). "Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)". Journal of Translational Medicine. 19 (1): 162. doi:10.1186/s12967-021-02833-2. ISSN 1479-5876. PMC 8058748. PMID 33882940.